Jose Fernando Moura: Phase 2 PERLA trial shows a new option in same setting NSCLC 1st line.

Jose Fernando Moura: Phase 2 PERLA trial shows a new option in same setting NSCLC 1st line.

Jose Fernando Moura, Oncologist and Principal Investigator in Solid Tumors at Real Hospital Portuguese and IMIP, shared on X/Twitter from ESMO23:

“One more for the team! Phase 2 PERLA trial shows a new option in same setting NSCLC 1st line similar activity.”

Jose Fernando Moura: Phase 2 PERLA trial shows a new option in same setting NSCLC 1st line.

Source: Jose Fernando Moura/Twitter.

cancer ESMO23 Jose Fernando Moura NSCLC OncoDaily Oncology PERLA trial Solange Peters